Myasthenia gravis: Newer therapies offer sustained improvement

  • Cleveland Clinic Journal of Medicine
  • November 2013,
  • 80
  • (11)
  • 711-721;
  • DOI: https://doi.org/10.3949/ccjm.80a.13044

ABSTRACT

Myasthenia gravis is a prototypical antibody-mediated autoimmune neuromuscular disorder. Treatments have improved over the past 30 years, leading to significantly fewer deaths and better quality of life. Future research should further elucidate its pathogenesis, reveal better ways to diagnose it, and yield new treatments.

View Abstract
Loading
  • Print
  • Download PDF
  • Article Alerts
  • Email Article
  • Citation Tools
  • Share

Jump to section